<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04274335</url>
  </required_header>
  <id_info>
    <org_study_id>2020-KEP-401</org_study_id>
    <nct_id>NCT04274335</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Pharmacodynamics of Tranexamic Acid in Women Having Caesarean Section Birth [WOMAN-PharmacoTXA]</brief_title>
  <official_title>A Randomised Controlled Trial to Assess the Pharmacokinetics and Pharmacodynamics of Intramuscular, Intravenous and Oral Administration of Tranexamic Acid in Women Giving Birth by Caesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rawalpindi Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>London School of Hygiene and Tropical Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intramuscular injection and oral solution of tranexamic acid (TXA) would increase its use in&#xD;
      situations where administration of intravenous drugs is difficult. The investigators aim to&#xD;
      assess the population pharmacokinetics (PK) and pharmacodynamics (PD) of intravenous,&#xD;
      intramuscular and oral TXA in women undergoing undergoing caesarean section (CS) with at&#xD;
      least one known risk factor for postpartum haemorrhage (PPH)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label, randomised controlled trial to assess the pharmacokinetics and&#xD;
      pharmacodynamics of intramuscular, intravenous and oral solution administration of tranexamic&#xD;
      acid in women giving birth by caesarean section. 120 women (30 receiving oral liquid, 30&#xD;
      receiving intramuscular, 30 receiving intravenous and 30 receiving no TXA who have at least 6&#xD;
      evaluable PK samples will be randomised.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic</measure>
    <time_frame>24 hours after randomisation</time_frame>
    <description>Concentration of TXA in Maternal blood over time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Placenta transfer of TXA</measure>
    <time_frame>at birth of baby</time_frame>
    <description>Concentrations of TXA in placenta cord blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placenta transfer of TXA</measure>
    <time_frame>within 24 hours of birth</time_frame>
    <description>Concentration of neonate TXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of D-dimer</measure>
    <time_frame>up to 24 hours after randomisation</time_frame>
    <description>Maternal blood concentration over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal blood volume lost</measure>
    <time_frame>from incision to 2 hours from CS</time_frame>
    <description>total blood loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of Injection site reaction from IM administration</measure>
    <time_frame>from randomisation up to 7 days after</time_frame>
    <description>Local reactions at injection site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse events (maternal and neonate)</measure>
    <time_frame>from randomisation up to 7 days after</time_frame>
    <description>any untoward medical events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of women with a clinical diagnosis of PPH</measure>
    <time_frame>up to 24 hours after giving birth</time_frame>
    <description>total blood loss of &gt;1000 mL or any blood loss sufficient to cause haemodynamic instability or requires treatment</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Pregnancy, High Risk</condition>
  <arm_group>
    <arm_group_label>Intravenous tranexamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intramuscular tranexamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral liquid tranexamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No tranexamic acid</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid 100Mg/Ml Inj Vil 10Ml</intervention_name>
    <description>1 gram of tranexamic acid to be administered intravenously</description>
    <arm_group_label>Intravenous tranexamic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid Oral Solution</intervention_name>
    <description>4 grams of tranexamic acid given as an oral solution</description>
    <arm_group_label>Oral liquid tranexamic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid Injectable Product</intervention_name>
    <description>1 gram of tranexamic acid given as 2 separate intramuscular injection</description>
    <arm_group_label>Intramuscular tranexamic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women admitted to hospital giving birth by CS&#xD;
&#xD;
          -  History of at least one risk factor for PPH&#xD;
&#xD;
          -  Adult (â‰¥18 years old)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women giving birth vaginally&#xD;
&#xD;
          -  Women with a known allergy to TXA or its excipients&#xD;
&#xD;
          -  Women with current antepartum haemorrhage&#xD;
&#xD;
          -  Women known to have received TXA within 48 hours prior to randomisation&#xD;
&#xD;
          -  Women with known renal impairment&#xD;
&#xD;
          -  Women with any known blood clotting disorder&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women giving birth by caesarean section</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haleema Shakur-Still</last_name>
    <role>Study Chair</role>
    <affiliation>London School of Hygiene and Tropical Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ian Roberts</last_name>
    <role>Study Chair</role>
    <affiliation>London School of Hygiene and Tropical Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haleema Shakur-Still</last_name>
    <phone>+44 207 958 8113</phone>
    <email>Haleema.Shakur@lshtm.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>MCH PIMS</name>
      <address>
        <city>Islamabad</city>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S Batool</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Women and Newborn Hospital</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>K Lubeya</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Pakistan</country>
    <country>Zambia</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 14, 2020</study_first_submitted>
  <study_first_submitted_qc>February 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Totally anonymised dataset used for main analysis will be made freely available</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>freely available 1 year after main publication</ipd_time_frame>
    <ipd_access_criteria>Free login to website required for monitoring usage of data</ipd_access_criteria>
    <ipd_url>https://freebird.lshtm.ac.uk</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

